Use the hyperlinks, where available to access additional clinical trial information.
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Children's Oncology Group
Other Non-Commercial Sponsor
National Cancer Institute (NCI)
This is a non-randomised trial with two experimental arms. Participants with new diagnosed diffuse anaplastic Wilm's Tumour (DAWT) will receive a regimen of UH-3, consisting of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with favourable histology Wilm's Tumour (FHWT) that has come back (relapsed) will receive a regimen of ICE/Cyclo/Topo, consisting of ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan.